Preventative drug shown to stop spread of cancer as study on mice finds ‘90% effectiveness’

Cancer metastasis is the primary cause of death among cancer patients.
A new study may be able to prevent metastasisation.
National Cancer Institute/Unsplash
Jessica Knibbs20 January 2023

Metastasisation - the spreading of cancer cells from the primary tumour into surrounding body tissues and organs - is the leading cause of death in cancer patients.

Now a new study has found a potential way to stop these cancer cells from entering a person’s blood.

Scientists from Israel are working to produce the world’s first preventative drug to help stop tumours that cause secondary cancer, as reported by The Times of Israel.

The active ingredient in the drug has shown 90 per cent effectiveness when studied on mice.

What the study found and how it could help cancer patients

Current drugs against cancer have worked by reducing the growth of the primary tumour but, until now, no treatment has been available to eradicate metastatic cancer.

The research team at Bar Ilan University has produced a peptide which stops cancer cells from entering the blood and halting any movement to other body parts.

The research was published in a peer-reviewed study and has been successfully shown to help prevent metastasis in mice.

It could mean the drug can be used as a preventative measure when it comes to stopping the spread of diseased cells which cause secondary cancer.

Stopping the spread of secondary tumours

Chemotherapy helps to eradicate cancer cells as much as possible. However, it has little effect on stopping cancer cells from rapidly increasing.

The research team believes this new peptide - a chain of amino acids – will be successful on all solid tumours.

According to the efficacy rate, mice with breast cancer who received the peptide were at least 90 per cent less likely than the control group to develop secondary tumours.

Professor Jordan Chill, a co-author of the paper, said of this new discovery: “We think this may impede metastasis by stopping the invadopodia from activating.

“I anticipate it might be used with chemotherapy or other cancer-cell-killing therapies,” he added.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in